阿托伐他汀治疗糖尿病伴高血压患者的疗效及对尿β<sub>2</sub>-MG、SCr、HbAlc水平的影响

doi:10.3969/j.issn.1671-7171.2017.04.002

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical effects of atorvastatin in the treatment of diabetic patients with hypertension and its effects on levels of urine β₂ microglobulin (β₂-MG), serum creatinine (Scr) and glycosylated hemoglobin (HbA1c). 【Methods】Eighty-six patients with diabetes and hypertension were randomly divided into the control group and the observation group, with 43 cases in each group. The control group was given conventional symptomatic treatment, while the observation group was additionally treated with atorvastatin. The therapeutic effects were compared between the two groups. The changes of levels of urine β₂-MG, Scr, HbA1c, total cholesterol (TC), triacylglycerol (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), high-sensitivity C reactive protein (hs-CRP), and interleukin -6 (IL-6) before and after treatment were determined; the incidence of adverse reactions was statistically analyzed. 【Results】 The total effective rate was 95.35% (41/43) in the observation group, which was higher than that in the control group (79.70%, 34/43); the difference was statistically significant (χ²=5.107,P=0.023). Before treatment, the indexes showed no significant differences between the two groups (P>0.05). After treatment, the levels of β₂-MG, Scr, HbA1c, TC, LDL-C, IL-6, and hs-CRP decreased P<0.05)-the decrease in the observation group was greater than that in the control group (all P<0.05). 【Conclusion】 Atorvastatin is effective in the treatment of diabetic patients with hypertension. It can reduce the levels of blood lipids and inflammatory factors as well as improve renal function.

Key words： Diabetes Complications Hypertension/CO Simvastatin/TU Antilipemic Agents/TU beta 2-Microglobulin/UR Creatinine/BL

Received: 27 December 2016

PACS:

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Li-hua
	HAN Xiao-jun
	SU Ru-ting

Cite this article:

JIANG Li-hua,HAN Xiao-jun,SU Ru-ting. Clinical Efficacy of Atorvastatin on Diabetic Patients with Hypertension and its Effects on Urinary β₂-MG, SCr and HbAlc Levels[J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(4): 628-631,634.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.04.002 OR http://www.jcr.net.cn/EN/Y2017/V34/I4/628

[1] 邢湘君.坎地沙坦酯联用氨氯地平/阿托伐他汀钙治疗糖尿病并发高血压70例[J].医药导报,2013,32(7):904-906.
[2] 张瑶,汪力,高芳,等.阿托伐他汀对糖尿病肾病微炎症状态的影响[J].西部医学,2016,28(2):215-217,220.
[3] 赵建.阿托伐他汀对2型糖尿病患者血脂及氧化应激的影响[J].医学临床研究,2010,27(2):303-304,307.
[4] 徐向进, 潘长玉, 田慧,等. WHO及美国糖尿病学会糖尿病诊断标准在老年人群中应用的分析和评估[J].中华内分泌代谢杂志, 2002, 18(5):357-361.
[5] 郭艺芳, 张靖. 美国高血压协会/国际高血压协会社区高血压管理临床实践指南简介[J].中国医学前沿杂志电子版, 2014, 6(1):83-86.
[6] 曾正洪.阿托伐他汀钙治疗2型糖尿病血脂异常患者的临床疗效[J].医学临床研究,2013,15(11):2218-2219.
[7] 文英郭,朱才忠.阿托伐他汀对2型糖尿病合并高血压患者尿β₂-微球蛋白及炎性指标的早期干预效果[J].中国老年学杂志,2016,36(6):1342-1343.
[8] 邹文博,苏津自,许昌声,等.阿托伐他汀对碘普罗胺引起的糖尿病大鼠肾小管上皮细胞凋亡的影响[J].中国病理生理杂志,2013,29(8):1393-1399.
[9] 刘超,郑桃林,戴忠友,等.血清CYS-C、Hcy、MMP-9水平与中老年人2型糖尿病合并脑梗死的相关性研究[J].湖南师范大学学报(医学版),2016,13(3):28-30.
[10] 赵辉.阿托伐他汀钙对2型糖尿病合并高血压患者血脂和炎症指标的影响[J].宁夏医科大学学报,2015,37(12):1442.
[11] 刘春荣,宋巧凤,王希柱,等.阿托伐他汀联合依折麦布对高血压合并糖尿病患者NT-proBNP和炎症指标的影响[J].河北医药,2012,34(21):3254-3256.
[12] 张灵,田国祥,魏万林,等.阿司匹林联合阿托伐他汀对高血压病合并糖尿病伴早期肾损害患者动脉僵硬度的影响[J].中国动脉硬化杂志,2013,21(8):745-750.
[13] 刘涛,王辉山,陶登顺,等.阿托伐他汀早期干预对2型糖尿病合并高血压患者血脂及炎症因子水平的影响[J].现代生物医学进展,2015,15(33):6491-6493.
(本文编辑:邓丽萍) [收稿日期] 2016-12-27

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(4): 795-797.